BioCryst Pharmaceuticals | BCRX - Cost Of Sales


BioCryst Pharmaceuticals reported $3.84M in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
BioCryst Pharmaceuticals USD 3.84M 5.68M Jun/2026
Chugai Pharma JPY 104.22B 11.43B Jun/2026
Daiichi Sankyo JPY 124.29B 6.02B Jun/2026
Gilead Sciences USD 1000M 445M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
Glaxosmithkline GBP 1.88B 1.6B Mar/2026
Incyte USD 104.96M 457K Jun/2026
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
Karyopharm Therapeutics USD 1.34M 139K Mar/2026
Neurocrine Biosciences USD 39.4M 25.6M Jun/2026
Novavax USD 22.1M 608K Dec/2025
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Roche Holding CHF 7.85B 630M Jun/2026
Sarepta Therapeutics USD 150.1M 40.64M Jun/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vertex Pharmaceuticals USD 489.2M 96.4M Jun/2026